Rydex Health Care A holds a quantitatively derived Negative Morningstar Medalist Rating. The rating indicates the model sees limited potential for the strategy to outperform peers on a risk-adjusted basis over a full market cycle.
Rydex Health Care Fund Class A RYHEX
- NAV / 1-Day Return $140.02 / +0.21 %
- Fund Size $26.8M
- Adjusted Expense Ratio 1.640%
- Net Expense Ratio 1.640%
- Fee Level: Distribution High
- Share Class Type Front Load
- Morningstar Category Health
- Equity Style Box (Funds) Mid Blend
- Minimum Initial Investment $2,500
- Investment Status Open
- TTM Yield 0.00%
- Turnover Ratio 244%
Morningstar’s Analysis RYHEX
Will RYHEX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 24.4
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Eli Lilly and Co | 3.86 | 849,040 | Healthcare |
Johnson & Johnson | 3.33 | 731,353 | Healthcare |
AbbVie Inc | 2.83 | 622,844 | Healthcare |
Merck & Co Inc | 2.59 | 568,876 | Healthcare |
UnitedHealth Group Inc | 2.29 | 504,286 | Healthcare |
Thermo Fisher Scientific Inc | 2.18 | 479,487 | Healthcare |
Amgen Inc | 2.04 | 448,365 | Healthcare |
Abbott Laboratories | 1.90 | 417,602 | Healthcare |
Gilead Sciences Inc | 1.77 | 389,557 | Healthcare |
Pfizer Inc | 1.63 | 358,624 | Healthcare |